Literature DB >> 7910650

GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats.

R Deghenghi1, M M Cananzi, A Torsello, C Battisti, E E Muller, V Locatelli.   

Abstract

In recent years several synthetic peptides have been shown to be active in inducing GH secretion in different mammalian species. Among them GHRP-6, GHRP-1 and GHRP-2 have demonstrated high effectiveness and high selectivity in stimulating GH release. In the present paper we report studies on the GH-secreting properties of a GHRP analog in which Trp was substituted with the chemically more stable 2-Methyl-Trp. In studies performed in conscious 10-day old rats, the hexapeptide Hexarelin (His-D-2Me-Trp-Ala-Trp-D-Phe-Lys-NH2) resulted very active in stimulating GH secretion. In anesthetized adult male rats, i.v. administration of GHRP-6 or Hexarelin elicited prompt GH release with peak GH levels occurring within 10 min At all the doses tested, the 2 peptides possessed similar effectiveness in stimulating GH release. Hexarelin given s.c. elicited a long-lasting GH release and was slightly more effective than GHRP-6. In conclusion, these findings indicate that Hexarelin is a highly effective GH releaser and might represent a valuable diagnostic and/or therapeutic tool in clinical practice.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7910650     DOI: 10.1016/0024-3205(94)00510-9

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  25 in total

Review 1.  Intranasally and orally active GH secretagogues are useful clinical tools: so why are they not on the market?

Authors:  Z Laron
Journal:  J Endocrinol Invest       Date:  2003-01       Impact factor: 4.256

2.  Hepatic extraction of hexarelin, a new peptidic GH secretagogue, in the isolated perfused rat liver.

Authors:  M Roumi; S Marleau; M Boghen; M Nilsson; P Du Souich; H Ong
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

Review 3.  Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases.

Authors:  Rasha Mofeed Habeeb Mosa; Zhen Zhang; Renfu Shao; Chao Deng; Jiezhong Chen; Chen Chen
Journal:  Endocrine       Date:  2015-02-04       Impact factor: 3.633

4.  Hexarelin: a multi-receptor peptide.

Authors:  R Deghenghi
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

5.  JMV2894, a novel growth hormone secretagogue, accelerates body mass recovery in an experimental model of cachexia.

Authors:  Elena Bresciani; Laura Rizzi; Laura Molteni; Monica Ravelli; Antonella Liantonio; Khoubaib Ben Haj Salah; Jean-Alain Fehrentz; Jean Martinez; Robert J Omeljaniuk; Giuseppe Biagini; Vittorio Locatelli; Antonio Torsello
Journal:  Endocrine       Date:  2016-11-28       Impact factor: 3.633

6.  Interaction of the novel GH secretagogue hexarelin with GHRH in regulating the secretion of GH by cultured human pituitary somatotrophinomas in vitro.

Authors:  Q Liu; T Lei; K Liu; W Lin; E F Adams
Journal:  J Tongji Med Univ       Date:  2000

7.  Effects of the novel GH secretogogue, hexarelin on GH secretion and phosphatidylinositol hydrolysis by human pituitary somatotrophinomas in cell culture.

Authors:  Q Liu; T Lei; K Liu; X Bai; E Adams
Journal:  J Tongji Med Univ       Date:  1999

8.  Lack of effect of hexarelin on TRH-induced TSH response in normal adult man.

Authors:  M Arosio; G Casati; O Biella; S Porretti; B P Imbimbo; G Faglia
Journal:  J Endocrinol Invest       Date:  1998-04       Impact factor: 4.256

9.  Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man.

Authors:  E Arvat; L Gianotti; J Ramunni; L DiVito; R Deghenghi; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

10.  The growth hormone response to hexarelin in patients with Prader-Willi syndrome.

Authors:  M Cappa; G Raguso; T Palmiotto; A Faedda; F Gurreri; G Neri; R Deghenghi; S Loche
Journal:  J Endocrinol Invest       Date:  1998-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.